Reviewing Treatment Protocols

Documents to Request

• Current NCCN guideline version for the specific cancer type
• Complete staging workup documentation
• Molecular and biomarker test results (PD-L1, MSI, TMB, driver mutations)
• Pathology report with histologic grade and subtype
• Prior treatment history with response and toxicity documentation
• Organ function labs (renal, hepatic, cardiac, hematologic)
• Imaging reports establishing baseline disease burden
• Insurance authorization requirements or formulary restrictions

Step 1: Verify Diagnosis Classification and Guideline Mapping

Confirm the diagnosis maps to the correct NCCN guideline. Many cancers have distinct guidelines by subtype:

Verify the proposed treatment falls within the correct guideline decision pathway node. Trace the algorithm from diagnosis through biomarker status to the specific treatment recommendation.

Step 2: Evaluate Treatment Recommendation Against NCCN Categories of Evidence

NCCN categories of evidence and consensus:

For each component of the proposed treatment plan, document:

• The specific NCCN recommendation and its evidence category
• Whether the recommendation is "preferred," "other recommended," or "useful in certain circumstances"
• The guideline version and page/node reference
• Whether biomarker-directed therapy is indicated and correctly selected

Flag any regimen not found in the current NCCN guideline as "off-pathway" and require documented justification.

Step 3: Assess Dose, Schedule, and Supportive Care Compliance

Review the proposed regimen for:

• Dose accuracy: Verify mg/m² or mg/kg calculations against NCCN-specified doses. Common error: using flat dosing where weight-based is specified (e.g., pembrolizumab 200mg flat vs. 2mg/kg).
• Schedule concordance: Confirm cycle length, treatment days, and total planned cycles match guideline recommendations.
• Supportive care: Verify appropriate antiemetic regimen per NCCN Antiemesis guidelines (high vs. moderate vs. low emetogenic potential). Confirm G-CSF prophylaxis for regimens with >20% febrile neutropenia risk per NCCN Hematopoietic Growth Factors guideline.
• Pre-medications: Confirm required premedications (e.g., dexamethasone for taxanes, acetaminophen/diphenhydramine for rituximab).
• Monitoring requirements: Verify mandated monitoring (e.g., LVEF for trastuzumab, LFTs for checkpoint inhibitors, EKG for certain TKIs).

Step 4: Document Alternatives and Deviations

For each treatment component:

1. List NCCN-preferred alternatives at the same decision node
2. If the proposed treatment deviates from preferred options, document the rationale category:
   • Patient comorbidity (specify organ dysfunction or interaction)
   • Prior treatment history (progression on preferred agent)
   • Molecular profile directing alternative selection
   • Patient preference with informed consent documentation
   • Clinical trial enrollment
   • Drug availability or access limitation
3. Rate the deviation severity: minor (within guideline options), moderate (guideline-listed but not recommended for this node), major (not in current guideline)

Step 5: Generate Concordance Summary Report

Structure the final review as:

1. Concordance determination: Concordant / Concordant with minor deviation / Non-concordant
2. Evidence level for each treatment component with NCCN category
3. Identified gaps: Missing biomarker testing, incomplete staging, unsupported dose modifications
4. Alternative recommendations ranked by evidence level
5. Required actions before treatment initiation (e.g., complete HER2 testing, obtain cardiac clearance)
6. Payer considerations: Note if the regimen qualifies for NCCN Compendium coverage or requires prior authorization with clinical rationale

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Does the review reference the current NCCN guideline version (not an outdated edition)?
2. Are all NCCN evidence categories correctly cited for each recommendation?
3. Have all guideline-required biomarker tests been verified as completed or flagged as pending?
4. Are dose modifications and supportive care reviewed against relevant NCCN supportive care guidelines?
5. Is the concordance determination clearly stated with supporting rationale?

Quality Audit

• Correct NCCN guideline identified for cancer type and subtype
• Guideline version number and date documented
• Treatment mapped to specific algorithm decision node
• Evidence category (1, 2A, 2B, 3) cited for each recommendation
• Preferred vs. other recommended vs. useful in certain circumstances distinction documented
• Dose accuracy verified against guideline-specified regimen
• Cycle schedule and duration match guideline recommendations
• Required biomarker testing confirmed complete or flagged
• Supportive care (antiemetics, G-CSF, premedications) evaluated
• Treatment deviations documented with rationale category
• Alternative regimens listed with evidence levels
• Payer coverage implications noted
• Concordance determination clearly stated
• No references to superseded guideline versions

Guidelines

• Always reference the most current NCCN guideline version — guidelines are updated multiple times per year
• Never assume a regimen is concordant without tracing the algorithm from diagnosis through biomarkers to the specific treatment node
• NCCN Category 2A is the default for most recommendations — absence of a category label means 2A
• "Preferred" designation is stronger than "other recommended" and should be the default recommendation
• Off-label use of approved drugs must still be evaluated for NCCN Compendium listing for coverage purposes
• Document whether the treatment intent (curative vs. palliative) aligns with the stage and guideline pathway
• Flag any regimen that lacks NCCN listing — this is a major payer coverage risk
• When multiple equivalent options exist, note patient-specific factors that favor one over another